AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02556385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency rTMS
Description: Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
Study NCT02556385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency rTMS
Description: Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
Study NCT03472885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Participants received a daily oral dose of danicopan TID during the treatment period.
Study NCT03472885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
Study NCT01601236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups \[8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)\].
Study NCT01601236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
Study NCT02937116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Study NCT02937116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\Cisplatinum\Pemetrexed
Study NCT02937116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\cisplatin\gemcitabine
Study NCT02937116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\oxaliplatin\capecitabine
Study NCT02937116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\etoposide\cisplatin
Study NCT02937116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308\irinotecan\5-FU
Study NCT03882606 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Scharioth Macula Lens (SML, Medicontur)
Description: magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient
Study NCT03079622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electric Vacuum Aspiration
Study NCT03079622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Vacuum Aspiration
Study NCT01507259 — intervention group
Intervention type: OTHER
Intervention: cocoa
Description: 70% versus 34%
Study NCT01074814 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Approved therapy will be assigned based on molecular profile and RPMA results
Description: treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results
Study NCT03599674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Bridge Program
Description: Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
Study NCT02066181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT02066181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT02066181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02066181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Optional ancillary studies
Study NCT02066181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Optional ancillary studies
Study NCT02066181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT01440712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin
Description: Administration of 100 ml of gastrografin by the nasogastric tube, only once.
Study NCT01440712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological serum
Description: Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
Study NCT04214158 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: Assessment
Study NCT02175004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotersen
Description: Inotersen SC
Study NCT01208493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preterm infant formula with high protein levels
Description: minimum 3 weeks feeding until hospital discharge
Study NCT03937570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echo-optimization
Description: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
Study NCT00224575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnosis reassessment
Description: Strategy of diagnosis reassessment following a decision tree.
Study NCT00224575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnosis strategy and subsequent therapeutic reassessment
Description: Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
Study NCT00628667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg orally twice daily
Study NCT00628667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02144610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGF Plasmid (AMG0001)
Description: IM
Study NCT02144610 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: IM
Study NCT03408093 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
Study NCT02558088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Study NCT01453218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATeGe-Fresenius
Description: Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
Study NCT01208493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preterm standard infant formula
Description: minimum 3 weeks feeding until hospital discharge
Study NCT02038543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyproline and Leucine
Description: Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
Study NCT02686905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewable Multivitamin with Iron
Description: Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
Study NCT02686905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PatchMD Vitamin D3/Calcium Patch
Description: Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
Study NCT02686905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PatchMD Multivitamin Patch
Description: Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
Study NCT02686905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PatchMD B12 Energy Plus Patch
Description: Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
Study NCT02686905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewable Calcium
Description: Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
Study NCT02686905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quick Dissolve B12
Description: Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
Study NCT02179099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTX mixed with TC-3 Gel
Description: Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
Study NCT03257020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
Study NCT00655863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and Pioglitazone
Description: Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
Study NCT00655863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Study NCT00655863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Study NCT01450254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy Biomechanical System
Description: The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
Study NCT01450254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention will be prescribed to the control group during participation in the study.
Study NCT00568802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study NCT00568802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match hydroxyurea
Study NCT00900744 — intervention group
Intervention type: DRUG
Intervention: Tamoxifen
Description: 20 mg daily
Study NCT02416804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -> 10 μg/hr -> 15 (5+10) μg/hr -> 20 μg/hr
Study NCT02416804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -> 200 mg/d -> 250 mg/d -> 300 mg/d
Study NCT04295876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BRIDGES Project Intervention
Description: The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.
Study NCT02777723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenobella
Description: Hypotonic 0.3% Sodium Hyaluronate
Study NCT02777723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic 0.3% Sodium Hyaluronate
Description: Isotonic 0.3% Sodium Hyaluronate
Study NCT01139021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
Study NCT04262973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: six-hour dementia care course
Study NCT04262973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education and workshop
Description: six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice
Study NCT01012739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg via the Concept1 dry-powder inhaler
Description: Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
Study NCT01012739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 60 μg via the Simoon dry-powder inhaler
Description: Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
Study NCT01012739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 120 μg via the Simoon dry-powder inhaler
Description: Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
Study NCT01639378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Symplicity Catheter System
Study NCT01012739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol via the Concept1 dry-powder inhaler
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
Study NCT03401229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg SC + Mometasone Furoate
Description: Benralizumab injection is 30mg/ml SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Benralizumab 30 mg SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study.
Study NCT03401229 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo SC + Mometasone Furoate
Description: Matching placebo injection is SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Matching placebo SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study.
Study NCT02088437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Description: additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
Study NCT02088437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: once daily physiotherapy whilst acute hospital inpatient
Study NCT03107104 — intervention group
Intervention type: DEVICE
Intervention: Topcon DRI OCT Triton (plus)
Description: The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes
Study NCT03107104 — intervention group
Intervention type: DEVICE
Intervention: TRC-50DX retinal camera
Description: The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
Study NCT01696110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
Study NCT01696110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: heparin monotherapy
Study NCT04384185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Exercises:~* Pelvic tilt.~* brinding.~* cuadruped arm/leg raise.~* Abdominal strengthening exercises.~* Low-back muscles stretching.~* The side bridge.~* Side leg separation
Study NCT04384185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: 1. Functional diaphragm balancing technique: gentle vertical pressure was applied for 5 minutes at the diaphragm level.~2. Muscle fiber stretching technique: a cranial traction was performed from the lower edge of the costal arches during the inspiratory breathing phase, for more than 10 respiratory cycles.~3. Phrenic-center inhibition technique (Figure 3C): the soft tissue was pumped during the expiratory phase by gently and simultaneously using both hands to create pressure in cranial and caudal direction, for more than 10 respiratory cycles.
Study NCT04269330 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
Description: Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
Study NCT04269330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
Description: Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
Study NCT00690820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase Delayed Release
Description: 12,000 unit Capsules, dosed individually based on fat intake.
Study NCT00690820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo